araag2/HINT huggingface dataset:
Clinical trial NCT02358668 (phase 2, status: completed)
Conditions: pre-diabetes
ICD codes: O24.32, O24.82, O24.02, O24.12, O24.33, O24.83, O24.03
Drugs: bti320, bti320 matching placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Adult subjects ≥ 18-70 years inclusive

          2. Chinese ethnicity

          3. High risk subject with pre-diabetes as defined by meeting at least 2 of the following
             criteria from (a), (b) and (c):

               1. FPG ≥ 5.6-6.9 mmol/l and/or 2-hour PG ≥ 7.8-11.0 mmol/l during 75 gram OGTT

               2. HbA1c ≥ 5.7-6.4%

               3. At least one of the following risk factors:-

                    -  History of gestational diabetes

                    -  Family history of diabetes in first degree relative

                    -  2 components or more of the metabolic syndrome (triglyceride ≥ 1.7 mmol/L,
                       blood pressure (BP) ≥ 130/80 mmHg, high density-lipoprotein (HDL)
                       cholesterol <1.3 mmol/L in women or <1.1 in men and waist circumference ≥ 80
                       cm in women or ≥ 90 cm in men). Patients on anti-hypertensive agent for
                       treatment of hypertension or lipid lowering drug for the treatment of
                       hyperlipidaemia will respectively be considered to have one component of the
                       metabolic syndrome.

          4. Subject is capable of giving informed consent prior to the initiation of any study
             related procedures

          5. A female subject of childbearing potential who is sexually active with a
             non-sterilized male partner agrees to use routinely adequate and effective
             contraception to avoid pregnancy during the study period and up to 30 days after the
             final visit.

          6. The subject is able and willing to consistently record food diary to facilitate CGMS
             evaluation.

        Exclusion Criteria:

          1. Subject has received anti-diabetic agents within 6 weeks prior to screening visit.

          2. On dietary supplement known to affect glucose or galactose metabolism.

          3. History of acute cardiovascular disease including myocardial infarction, acute
             coronary syndrome or stroke which required hospitalization in the last 12 months.

          4. Significant renal impairment with estimated glomerular filtration rate (eGFR) <
             60ml/min/1.73m2

          5. Known lactose or galactose intolerance.

          6. History of eating disorder.

          7. Pregnant or lactating female subjects.

          8. Subjects with gastrointestinal disease that may interfere with absorption of the
             investigational product.

          9. Subject has received any investigational product within 30 days of randomization
             visit.

         10. Reduced life expectancy or any condition considered by the investigator as unsuitable
             for enrolment.
Clinical trial NCT02362230 (phase 2, status: terminated)
Conditions: metastatic breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: icotinib
SMILES: C#CC1=CC=CC(NC2=NC=NC3=CC4=C(OCCOCCOCCO4)C=C23)=C1
Reason stopped: 
    difficulty accruing subjects the study accrual was closed
  
Eligibility criteria:

        Inclusion Criteria:

          -  Age 18 years or older

          -  ECOG 0 or 1

          -  Primary or metastatic tumor onfirmed as triple negative

          -  Measurable disease per RECIST version 1.1

          -  normal organ function, including bone marrow function, renal function, liver function,
             and cardiac function

          -  Two or more prior chemotherapy

          -  signed and dated an informed consent form

          -  Life expectancy of at least 12 weeks

        Exclusion Criteria:

          -  Pregnant or breast feeding

          -  ECOG score ≧2

          -  Uncontrolled medical problems

          -  Hepatic, renal, or bone marrow dysfunction as detailed above

          -  Concurrent malignancy or history of other malignancy within the last five years except
             as noted above

          -  Patients were unable or unwilling to comply with program requirements
Clinical trial NCT02363621 (phase 2, status: completed)
Conditions: diabetic macular edema
ICD codes: E10.311, E10.319, E11.311, E11.319, E13.311, E13.319, E10.3513
Drugs: ranibizumab 0.3 mg, aflibercept 2.0 mg
SMILES: CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects will be eligible if the following criteria are met:

          -  Ability to provide written informed consent and comply with study assessments for the
             full duration of the study

          -  Age > 21 years

          -  Exam and OCT confirming Diabetic Macular Edema

          -  Visual Acuity of 20/400 or better

          -  No history of post injection pain or inflammation in the past

        Exclusion Criteria:

          -  Subjects who meet any of the following criteria will be excluded from this study

          -  History of Endophthalmitis in either eye

          -  Current inflammation in either eye

          -  Uncontrolled or symptomatic Dry Eye Syndrome

          -  Intravitreal injection less than 3 months ago

          -  History of Anterior or Posterior Uveitis

          -  History of post injection pain with prior treatments

          -  Recent thromboembolic event (<3 months)

          -  Pregnancy (positive pregnancy test) or lactation

          -  Premenopausal women not using adequate contraception.
Clinical trial NCT02365636 (phase 2, status: completed)
Conditions: postherpetic neuralgia
ICD codes: B02.22
Drugs: tv-45070, placebo
SMILES: FC(F)(F)C1=CC=C(CN2C(=O)[C@@]3(COC4=C3C=C3OCOC3=C4)C3=CC=CC=C23)O1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patient has chronic Postherpetic Neuralgia (PHN), defined as pain present for more
             than 6 months and less than 10 years after onset of herpes zoster skin rash affecting
             a single dermatome. Patients with more than 1 involved dermatome may also be included,
             provided the affected dermatomes are contiguous.

          -  Patient is ≥18 years of age, with a body mass index (BMI) between 18 and 34 kg/m2,
             inclusive, at the screening visit.

          -  If the patient is a woman and is fertile, the patient is not pregnant and has negative
             pregnancy tests at both the screening and randomization visits, and agrees to use an
             acceptable method of contraception for the duration of the study, including follow-up.

          -  If the patient is a man and is capable of producing offspring, the patient must agree
             to use an acceptable method of contraception, unless the partner cannot become
             pregnant for the duration of the study, including follow-up.

          -  Patient must sign the written Informed Consent Form (ICF) for the study and be willing
             to comply with all study procedures and restrictions.

          -  Patient must be judged by the investigator to be medically healthy (except for PHN)
             and able to participate in the study

               -  Other criteria apply, please contact the investigator for more information

        Exclusion Criteria:

          -  Patient has any other severe pain that might confound assessment or self-evaluation of
             pain due to PHN.

          -  Patient has PHN affecting the face (trigeminal nerve distribution).

          -  Patient has a history, in the judgment of the investigator, of inadequate response to
             more than 3 adequate courses of treatment with other medications used to treat
             neuropathic pain (eg, tricyclic antidepressants, serotonin-norepinephrine reuptake
             inhibitors, anticonvulsants, topical lidocaine, and/or topical capsaicin).

          -  Patient is taking oral analgesics (either opioid or non-opioid) or is receiving
             topical therapy such as the 5% topical lidocaine patch for the treatment of pain and
             is unwilling or unable to complete a washout period during which the patient will
             discontinue analgesic therapy or topical pain therapy.

          -  Patient has been treated with topical capsaicin at any time in the past 6 months for
             neuropathic pain.

          -  Patient has a history of fibromyalgia.

               -  Other criteria apply, please contact the investigator for more information
Clinical trial NCT02365649 (phase 2, status: completed)
Conditions: crohn's disease
ICD codes: K50.90, K50.913, K50.914, K50.911, K50.912, K50.918, K50.919
Drugs: abt-494, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Diagnosis of Crohn's disease (CD) for at least 90 days.

          2. Crohn's Disease Activity Index (CDAI) greater than or equal to 220 and less than or
             equal to 450.

          3. Subject inadequately responded to or experience intolerance to previous treatment with
             immunomodulators (e.g. azathioprine, 6-mercaptopurine, or methotrexate) and/or
             anti-TNF agent (e.g., infliximab, adalimumab, or certolizumab pegol).

        Exclusion Criteria:

          1. Subjects with ulcerative colitis (UC), collagenous colitis or indeterminate colitis.

          2. Subject who has had surgical bowel resections in the past 6 months or is planning
             resection.

          3. Subjects with an ostomy or ileoanal pouch.

          4. Subject with symptomatic bowel stricture or abdominal or peri-anal abcess.

          5. Subject who has short bowel syndrome.

          6. Subject with recurring infections or active Tuberculosis (TB).
Clinical trial NCT02366637 (phase 2, status: terminated)
Conditions: pulmonary disease, chronic obstructive
ICD codes: J44.9, J44.1, J44.0
Drugs: placebo, pf-03715455
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(C)(C)C1=NN(C(NC(O)=NCC2=CC=CC=C2SC2=CN3C(C=C2)=NN=C3C2=CC=CC=C2SCCO)=C1)C1=CC(Cl)=C(O)C=C1
Reason stopped: 
    study terminated on 7 april 2015 for business reasons. no safety and/or efficacy concerns
    contributed to the termination of the study
  
Eligibility criteria:

        Inclusion Criteria:

          -  Female subjects of non-childbearing potential and male subjects between the ages of 40
             and 80 years, inclusive

          -  Subjects with a diagnosis, for at least 6 months, of moderate to severe COPD and who
             meet the criteria for Stage II-III disease

          -  Subjects must have a smoking history of at least 10 pack-years

        Exclusion Criteria:

          -  Current evidence or history within the previous 6 months of any clinically significant
             disease (other than COPD) or abnormality in the opinion of the Investigator that would
             put the subject at risk or which would compromise the quality of the study data

          -  A COPD exacerbation requiring treatment with oral steroids or hospitalization for the
             treatment of COPD within 3 months of Screening
Clinical trial NCT02374853 (phase 2, status: terminated)
Conditions: infection
ICD codes: K94.02, K94.12, K94.22, K94.32, N99.511, A02.9, A31.0
Drugs: vancomycin
SMILES: CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)C2=C(N)C=CC=C2)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)[C@H](C)CC(O)=O
Reason stopped: 
    the preliminary analysis of study result did not show significant benefit that was anticipate
  
Eligibility criteria:

        Inclusion Criteria:

          -  Able to sign Informed Consent and Release of Medical Information Form

          -  Age ≥ 18 years

          -  Undergoing cardiac surgery with complete sternotomy (including re-operations)

        Exclusion Criteria:

          -  Evidence of active infection (any culture positive or blood positive infection)

          -  Undergoing organ transplantation

          -  Patients with known hypersensitivity to vancomycin

          -  Pregnant or nursing women

          -  Mental impairment or other conditions that may not allow participant to understand the
             nature, significance, and scope of study
Clinical trial NCT02378870 (phase 2, status: terminated)
Conditions: prostate cancer metastatic
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: osteodex, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    poor patient recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          1. Age ≥18 years at the time of signing the informed consent form.

          2. Histologically or cytologically confirmed diagnosis of adenocarcinoma of the prostate.

          3. Failing or not tolerating docetaxel therapy or for other reasons not suitable for such
             therapy and failing subsequent therapy with abiraterone and/or enzalutamide.

          4. Evidence of metastatic disease from bone scan (bone lesions) or other imaging
             modality.

          5. Evidence of PSA progression in two consecutive determinations at minimum 1 week
             interval.

          6. Castrate level of serum testosterone ≤1.7 nmol/L

          7. Performance status ECOG 0-2

          8. Laboratory requirements: Haematology: Neutrophils ≥ 1.5 x 109/l Hemoglobin ≥ 90 g/l
             Platelets ≥ 100 x 109/l Hepatic function: Total S-bilirubin ≤ 1.5 times the upper
             limit of normal (ULN) AST (SGOT) / ALT (SGPT) ≤ 2.5 times ULN Renal function:
             S-creatinine ≤ 1.5 times the upper limit of normal (ULN) Electrolytes: S-sodium,
             S-potassium, S-calcium (S-albumin corrected), S-phosphate, S-magnesium, all within
             normal ranges.

          9. No evidence (≤ 5 years) of prior malignancies (except successfully treated basal cell
             or squamous cell carcinoma of the skin).

         10. Able to adhere to the study visit schedule and other protocol requirements.

         11. Life expectancy ≥6 months

        Exclusion Criteria:

          1. Concurrent use of other anti-cancer agents or treatments, with the following
             exception: a stable dose of LHRH agonist/antagonist or polyestradiol phosphate
             bicalutamide. Washout period bicalutamide 6 weeks; after flutamide 4 weeks;
             abiraterone / enzalutamide 6 weeks.

          2. Any treatment modalities involving chemotherapy, radiation or major surgery within 4
             weeks prior to treatment in this study.

          3. Simultaneous participation in any other study involving investigational drugs or
             having participated in a study less than 4 weeks prior to start of study treatment.

          4. Any condition, including the presence of laboratory abnormalities, which confounds the
             ability to interpret data from the study or places the patient at unacceptable risk if
             he participates in the study.

          5. Plasma glucose level ≥7 mmol/l (or >120 mg/dl) at screening.

          6. Known brain metastases.

          7. Dental surgery (dental extraction), periodontal disease, local trauma including poorly
             fitting dentures within 6 months prior to the first dose of study drug.

          8. Treatment with bisphosphonates within 4 weeks prior to first dose of study medication.
Clinical trial NCT02378935 (phase 2, status: completed)
Conditions: hepatitis c virus infection
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: vox, sof/vel, rbv
SMILES: CC[C@@H]1[C@@H]2CN([C@@H]1C(=O)N[C@@]1(C[C@H]1C(F)F)C(=O)NS(=O)(=O)C1(C)CC1)C(=O)[C@@H](NC(=O)O[C@@H]1C[C@H]1CCCCC(F)(F)C1=C(O2)N=C2C=C(OC)C=CC2=N1)C(C)(C)C, [H][C@](N=C(O)OC)(C(C)C)C(=O)N1[C@@]([H])(C)CC[C@@]1([H])C1=NC2=C(N1)C1=CC3=C(C=C1C=C2)C1=C(CO3)C=C(C=C1)C1=CN=C(N1)[C@]1([H])C[C@]([H])(COC)CN1C(=O)[C@]([H])(N=C(O)OC)C1=CC=CC=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Individuals with chronic HCV infection

          -  HCV RNA ≥10^4 IU/mL at screening

          -  HCV genotype 1

          -  Cirrhosis determination; a liver biopsy may be required

          -  Screening laboratory values within defined thresholds

          -  Use of two contraception methods if female of childbearing potential or sexually
             active male

        Key Exclusion Criteria:

          -  Pregnant or nursing female

          -  Current or prior history of hepatic decompensation

          -  Hepatocellular carcinoma (HCC) or other clinically significant malignancy

          -  Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)

          -  History of clinically significant illness or any other medical disorder that may
             interfere with the individual's treatment, assessment or compliance with the protocol

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Clinical trial NCT02378961 (phase 2, status: completed)
Conditions: hepatitis c virus infection
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: vox, sof/vel
SMILES: CC[C@@H]1[C@@H]2CN([C@@H]1C(=O)N[C@@]1(C[C@H]1C(F)F)C(=O)NS(=O)(=O)C1(C)CC1)C(=O)[C@@H](NC(=O)O[C@@H]1C[C@H]1CCCCC(F)(F)C1=C(O2)N=C2C=C(OC)C=CC2=N1)C(C)(C)C, [H][C@](N=C(O)OC)(C(C)C)C(=O)N1[C@@]([H])(C)CC[C@@]1([H])C1=NC2=C(N1)C1=CC3=C(C=C1C=C2)C1=C(CO3)C=C(C=C1)C1=CN=C(N1)[C@]1([H])C[C@]([H])(COC)CN1C(=O)[C@]([H])(N=C(O)OC)C1=CC=CC=C1
Eligibility criteria:

        Key Inclusion Criteria:

          -  Individuals with chronic HCV infection

          -  HCV RNA ≥10^4 IU/mL at screening

          -  HCV genotypes 2, 3, 4, 5, or 6

          -  Cirrhosis determination; a liver biopsy may be required

          -  Screening laboratory values within defined thresholds

          -  Use of two contraception methods if female of childbearing potential or sexually
             active male

        Key Exclusion Criteria:

          -  Pregnant or nursing female

          -  Current or prior history of hepatic decompensation

          -  Hepatocellular carcinoma (HCC) or other clinically significant malignancy

          -  Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)

          -  History of clinically significant illness or any other medical disorder that may
             interfere with the individual's treatment, assessment or compliance with the protocol

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Clinical trial NCT02383940 (phase 2, status: completed)
Conditions: type 1 diabetes mellitus
ICD codes: E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: sotagliflozin, placebo
SMILES: CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Participant had given written informed consent.

          -  Young adult participants >=18 to <=30 years old at Screening, with a confirmed
             diagnosis of T1DM made at least 1 year prior to informed consent.

          -  Participants were being treated with insulin or insulin analogue delivered via
             continuous subcutaneous insulin infusion (CSII) or multiple daily injections (MDI).

          -  At Screening, must had A1C >= 9.0%.

          -  Must be willing and able to perform self-monitored blood glucose (SMBG) and complete
             the study diary.

          -  Females of childbearing potential must use an adequate method of contraception and had
             a negative pregnancy test.

        Exclusion Criteria:

          -  Any prior use of LX4211/sotagliflozin.

          -  Use of antidiabetic agent other than insulin or insulin analogue at the time of
             screening.

          -  Use of sodium-glucose cotransporter (SGLT) inhibitors within 8 weeks prior to start of
             the placebo Run-in Period.

          -  Chronic systemic corticosteroid use.

          -  Type 2 diabetes, or severely uncontrolled diabetes mellitus as determined by the
             Investigator.

          -  History of diabetic ketoacidosis (DKA) or nonketotic hyperosmolar state within 6
             months prior to the Screening Visit.

          -  History of severe hypoglycemic event within 1 month prior to the Screening Visit.
Clinical trial NCT02384382 (phase 2, status: completed)
Conditions: prostate carcinoma metastatic to the bone, castration resistant prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: enzalutamide
SMILES: CNC(=O)C1=C(F)C=C(C=C1)N1C(=S)N(C(=O)C1(C)C)C1=CC=C(C#N)C(=C1)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed adenocarcinoma of the prostate without
             neuroendocrine differentiation, or signet cell or small cell features;

          -  Presence of bone metastatic disease as assessed by at least two lesions on whole body
             metastable technetium-methylene diphosphonate (99mTc-MDP) bone scintigraphy;

          -  Throughout the study, ongoing androgen deprivation therapy with a luteinizing
             hormone-releasing hormone (LHRH) analogue or prior bilateral orchiectomy (medical or
             surgical castration);

          -  Testosterone ≤ 1.73 nmol/L (≤ 50 ng/dL) at screening;

          -  Progressive disease on androgen deprivation therapy at screening defined as a minimum
             of two sequentially rising prostate-specific antigen (PSA) values (PSA1 < PSA2 <
             PSA3);

          -  The screening PSA (PSA3) must be ≥ 2 μg/L (≥ 2 ng/mL).

        Exclusion Criteria:

          -  Prior enzalutamide, abiraterone acetate, aminoglutethimide, ketoconazole, radium Ra
             223 dichloride or other bone-targeting radionuclides, or cytotoxic chemotherapy in the
             CRPC setting for the treatment of prostate cancer or participation in a clinical trial
             of an investigational agent that inhibits the androgen receptor or androgen synthesis
             (unless treatment was placebo);

          -  Treatment with hormonal therapy (eg, androgen receptor inhibitors, 5-alpha reductase
             inhibitors) or biologic therapy for prostate cancer (other than LHRH analogue therapy)
             within 4 weeks before enrollment;

          -  Initiation of new treatment with denosumab, bisphosphonates, or systemic
             corticosteroids for treatment of prostate cancer within 4 weeks before enrollment;

          -  Use of an investigational agent within 4 weeks before the screening visit;

          -  Radiation therapy to bone within 4 weeks before enrollment;

          -  Use of opiate analgesics for prostate cancer pain within 4 weeks before enrollment;

          -  Screening 99mTc-MDP bone scintigraphy showing a superscan;

          -  Visceral (eg, lung, liver) metastatic disease. Adenopathy is allowed;

          -  Current or previously treated brain metastasis or active leptomeningeal disease;

          -  History of seizure any time in the past for any reason or any condition that may
             predispose to seizures.